


TICO

#ACC20/#WCCardio



AMERICAN
COLLEGE of
CARDIOLOGY

Trial Description: Patients undergoing PCI with an ultrathin biodegradable-polymer sirolimus-eluting stent for acute coronary syndrome were randomized to ticagrelor monotherapy after 3 months of DAPT vs. standard therapy.



RESULTS

- Primary outcome, death, myocardial infarction, stent thrombosis, stroke, target vessel revascularization, or TIMI major bleeding at 12 months: 3.9% of the ticagrelor monotherapy after 3 months of DAPT group vs. 5.9% of the standard therapy group ($p = 0.01$)
- Major bleeding: 1.7% of the ticagrelor monotherapy after 3 months group vs. 3.0% of the standard therapy group ($p = 0.02$)

CONCLUSIONS

- Among acute coronary syndrome patients who underwent PCI with an ultrathin biodegradable-polymer sirolimus-eluting stent, ticagrelor monotherapy after 3 months of DAPT was superior to standard therapy of DAPT for 12 months
- Ticagrelor monotherapy was effective at preventing net composite ischemic and bleeding events

Presented by Dr. Byeong-Keuk Kim at ACC.20/WCC